FORADIL
LOE ApproachingNDAINHALATIONPOWDER
Approved
Sep 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
FORADIL by Novartis is clinical pharmacology mechanism of action formoterol fumarate is a long-acting selective beta 2 -adrenergic receptor agonist (beta 2 -agonist). Approved for asthma, the prevention of bronchospasm only, such and 3 more indications. First approved in 2001.
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FORADIL (formoterol fumarate) is a long-acting beta-2 adrenergic receptor agonist (LABA) inhaled as a dry powder for maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It works by stimulating beta-2 receptors in bronchial smooth muscle to produce sustained bronchodilation and inhibit mast cell mediator release, with effects lasting 12 hours or longer.
LOE Approaching
Product is in late-stage patent life with moderate competitive pressure (30/100), signaling potential team rightsizing and transition to defensive market positioning.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Formoterol fumarate is a long-acting selective beta 2 -adrenergic receptor agonist (beta 2 -agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater…
Worked on FORADIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.